Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Warnock

Showing results (351-360 of 371) with videos related to

Pageof 38
Sort By:
JAMA|May 10, 2012
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rateKunihiro Matsushita, Bakhtawar K Mahmoodi, Mark Woodward, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 19, 2010
How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?Christiane Auray-Blais, Aimé Ntwari, Joe T R Clarke, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 25, 2013
Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry RegistryDominique P Germain, Frank Weidemann, Ademola Abiose, et al.
Journal of Medical Genetics|March 20, 2016
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry RegistryAlberto Ortiz, Ademola Abiose, Daniel G Bichet, et al.
Orphanet Journal of Rare Diseases|March 21, 2026
Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension studyMyrl Holida, Aleš Linhart, Nicola Longo, et al.
Journal of Inherited Metabolic Disease|October 9, 2024
A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapiesMyrl Holida, Aleš Linhart, Antonio Pisani, et al.
Molecular Genetics and Metabolism|November 27, 2007
Females with Fabry disease frequently have major organ involvement: lessons from the Fabry RegistryWilliam R Wilcox, João Paulo Oliveira, Robert J Hopkin, et al.
Plos One|August 8, 2015
Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused AgalsidaseDavid G Warnock, Daniel G Bichet, Myrl Holida, et al.
American Journal of Nephrology|March 8, 2013
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 17, 2009
Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)Agnes B Fogo, Leif Bostad, Einar Svarstad, et al.
Pageof 38

Showing results (351-360 of 371) with videos related to

Sort By:
Pageof 38
JAMA|May 10, 2012
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rateKunihiro Matsushita, Bakhtawar K Mahmoodi, Mark Woodward, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 19, 2010
How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?Christiane Auray-Blais, Aimé Ntwari, Joe T R Clarke, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 25, 2013
Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry RegistryDominique P Germain, Frank Weidemann, Ademola Abiose, et al.
Journal of Medical Genetics|March 20, 2016
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry RegistryAlberto Ortiz, Ademola Abiose, Daniel G Bichet, et al.
Orphanet Journal of Rare Diseases|March 21, 2026
Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension studyMyrl Holida, Aleš Linhart, Nicola Longo, et al.
Journal of Inherited Metabolic Disease|October 9, 2024
A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapiesMyrl Holida, Aleš Linhart, Antonio Pisani, et al.
Molecular Genetics and Metabolism|November 27, 2007
Females with Fabry disease frequently have major organ involvement: lessons from the Fabry RegistryWilliam R Wilcox, João Paulo Oliveira, Robert J Hopkin, et al.
Plos One|August 8, 2015
Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused AgalsidaseDavid G Warnock, Daniel G Bichet, Myrl Holida, et al.
American Journal of Nephrology|March 8, 2013
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 17, 2009
Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)Agnes B Fogo, Leif Bostad, Einar Svarstad, et al.
Pageof 38